Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection

Pharmaceutical Research

Volumn 15, Issue 6, 1998, Pages 819-825

  Peter, Katrin ^a,b   Gambertoglio, John G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

AIDS; Human immunodeficiency virus (HIV); Intracellular phosphorylation; Nucleoside reverse transcriptase inhibitors; Nucleoside therapy; Zidovudine

Indexed keywords

DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG ACTIVATION; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0031779845     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011956011207     Document Type: Review

References (50)

1. F. Barre-Sinoussi, J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-71 (1983).
2. R. C. Gallo, P. S. Sarin, E. P. Gelmann, M. Robert-Guroff, E. Richardson, V. S. Kalyanaraman, D. Mann, G. D. Sidhu, R. E. Stahl, S. Zolla-Pazner, J. Leibowitch, and M. Popovic. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865-7 (1983).
3. J. A. Levy, A. D. Hoffman, S. M. Kramer, J. A. Landis, J. M. Shimabukuro, and L. S. Oshiro. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840-2 (1984).
4. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-6 (1995).
5. X. Wei, S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-22 (1995).
6. M. Piatak, Jr., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-54 (1993).
7. J. Embretson, M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. T. Haase. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-62 (1993).
8. G. Pantaleo, C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-8 (1993).
9. D. A. Katzenstein. Antiretroviral therapy for human immunodeficiency virus infection in 1997. West J. Med. 166:319-25 (1997).
10. J. Balzarini. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16:113-26 (1994).
11. P. A. Furman, J. A. Fyfe, M. H. St Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-7 (1986).
12. Y. Tornevik, B. Jacobsson, S. Britton, and S. Eriksson. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses 7:751-9 (1991).
13. M. N. Dudley. Clinical pharmacokinetics of nucleoside antiretroviral agents. J. Infect. Dis. 171:S99-112 (1995).
14. T. P. Zimmerman, W. B. Mahony, and K. L. Prus. 3′-azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262:5748-54 (1987).
15. H. T. Ho and M. J. Hitchcock. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:844-9 (1989).
16. P. Hoggard, S. Khoo, M. Barry, and D. Back. Intracellular metabolism of zidovudine and stavudine in combination. J. Infect. Dis. 174:671-2 (1996).
17. D. A. Cooney, M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Balzarini, S. Broder, and D. G. Johns. Initial studies on the cellular pharmacology of 2′,3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35:2065-8 (1986).
18. N. Cammack, P. Rouse, C. L. Marr, P. J. Reid, R. E. Boehme, J. A. Coates, C. R. Penn, and J. M. Cameron. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-64 (1992).
19. G. J. Veal, P. G. Hoggard, M. G. Barry, S. Khoo, and D. J. Back. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS 10:546-8 (1996).
20. G. Ahluwalia, D. A. Cooney, H. Mitsuya, A. Fridland, K. P. Flora, Z. Hao, M. Dalal, S. Broder, and D. G. Johns. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36:3797-800 (1987).
21. M. A. Johnson and A. Fridland. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36:291-5 (1989).
22. J. F. Nave, A. Eschbach, D. Wolff-Kugel, S. Halazy, and J. Balzarini. Enzymatic phosphorylation and pyrophosphorylation of 2′,3′-dideoxyadenosine-5′-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2′,3′-dideoxyinosine. Biochem. Pharmacol. 48:1105-12 (1994).
23. W. Y. Gao, T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:2326-33 (1993).
24. W. Y. Gao, R. Agbaria, J. S. Driscoll, and H. Mitsuya. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-8 (1994).
25. A. J. Watson and L. M. Wilburn. Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides. AIDS Res. Hum. Retroviruses. 8:1221-7 (1992).
26. W. Y. Gao, D. G. Johns, and H. Mitsuya. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46:767-72 (1994).
27. F. Lori, A. Malykh, A. Cara, D. Sun, J. N. Weinstein J. Lisziewicz, and R. C. Gallo. Hydroxyurea as an inhibitor of Human immunodeficiency virus-type 1 replication. Science 266:801-5 (1994).
28. Z. Hao, D. A. Cooney, N. R. Hartman, C. F. Perno, A. Fridland, A. L. DeVico, M. G. Sarngadharan, S. Broder, and D. G. Johns. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34:431-5 (1988).
29. Z. Hao, D. A. Cooney, D. Farquhar, C. F. Perno, K. Zhang, R. Masood, Y. Wilson, N. R. Hartman, J. Balzarini, and D. G. Johns. Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate. Mol. Pharmacol. 37:157-63 (1990).
30. M. I. Bukrinsky, T. L. Stanwick, M. P. Dempsey, and M. Stevenson. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423-7 (1991).
31. J. A. Zack, S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-22 (1990).
32. J. A. Zack, A. M. Haislip, P. Krogstad, and I. S. Chen. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J. Virol. 66:1717-25 (1992).
33. T. Toyoshima, S. Kimura, S. Muramatsu, H. Takahagi, and K. Shimada. A sensitive nonisotopic method for the determination of intracellular azidothymidine 5′-mono-, 5′-di-, and 5′-triphosphate. Anal. Biochem. 196:302-7 (1991).
34. H. Kuster, M. Vogt, B. Joos, V. Nadai, and R. Luthy. A method for the quantification of intracellular zidovudine nucleotides. J. Infect Dis. 164:773-6 (1991).
35. B. N. Stretcher, A. J. Pesce, B. A. Geisler, and W. H. Vine. A coupled HPLC/radioimmunoassay for analysis of zidovudine metabolites in mononuclear cells. J. Liq. Chromatog. 14:2261-2272 (1991).
36. J. T. Slusher, S. K. Kuwahara, F. M. Hamzeh, L. D. Lewis, D. M. Kornhauser, and P. S. Lietman. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob. Agents Chemother. 36:2473-7 (1992).
37. K. Peter, J. P. Lalezari, and J. G. Gambertoglio. Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method. J. Pharm. Biomed. Anal. 14:491-9 (1996).
38. B. N. Stretcher, A. J. Pesce, P. T. Frame and D. S. Stein. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1541-7 (1994).
39. B. L. Robbins, J. Rodman, C. McDonald, R. V. Srinivas, P. M. Flynn, and A. Fridland. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 38:115-21 (1994).
40. E. G. Bridges, A. Faraj, and J. P. Sommadossi. Inhibition of mammalian DNA polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem. Pharmacol. 45:1571-6 (1993).
41. Y. Tornevik, B. Ullman, J. Baizarini, B. Wahren, and S. Eriksson. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829-37 (1995).
42. B. L. Robbins, B. H. Waibel, and A. Fridland. Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. Antimicrob. Agents Chemother. 40:2651-4 (1996).
43. M. Barry, M. Wild, G. Veal, D. Back, A. Breckenridge, R. Fox, N. Beeching, F. Nye, P. Carey, and D. Timmins. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 8:F1-5 (1994).
44. K. Peter and J. G. Gambertoglio. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Clin. Pharmacol. Ther. 60:168-76 (1996).
45. M. G. Barry, S. H. Khoo, G. J. Veal, P. G. Hoggard, S. E. Gibbons, E. G. Wilkins, O. Williams, A. M. Breckenridge, and D. J. Back. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10:1361-7 (1996).
46. V. I. Avramis, R. Kwock, M. M. Solorzano, and E. Gomperts. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J. Acquir. Immune Defic. Syndr. 6:1287-96 (1993).
47. S. Gollapudi and S. Gupta. Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochem. Biophys. Res. Commun. 171:1002-7 (1990).
48. S. Gupta and S. Gollapudi. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J. Clin. Immunol. 13:289-301 (1993).
49. G. Antonelli, O. Turriziani, M. Cianfriglia, E. Riva, G. Dong, A. Fattorossi and F. Dianzani. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res. Hum. Retroviruses. 8:1839-44 (1992).
50. S. Wu, X. Liu, M. M. Solorzano, R. Kwock, and V. I. Avramis. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 8:1-9 (1995).